In-Vitro Diagnostics Market to Reach US$131.68 Billion by 2032 as Infectious Disease, Oncology, Cardiology, Diabetes and Genetic Testing Demand Redefines Diagnostic Healthcare

NEW YORK, May 24, 2026 - According to DataM Intelligence, the global In-Vitro Diagnostics Market reached US$84.90 billion in 2024 and is expected to reach US$131.68 billion by 2032, growing at a CAGR of 5.0% during 2025 to 2032. The market is segmented by product type into instruments, reagents, software and services and others, by technique type into immunoassays, POC diagnostics, molecular diagnostics, hematology, tissue diagnostics, microbiology, self-blood-glucose monitoring and others, and by application into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, drug testing and others.

The global in-vitro diagnostics market is entering a stronger healthcare infrastructure cycle as hospitals, laboratories, clinics, home-care settings and precision medicine programs increase reliance on fast, accurate and scalable testing. On a growth-multiple basis, the market is expected to expand nearly 1.55x by 2032, reflecting the essential role of diagnostic testing in disease detection, treatment planning, patient monitoring and healthcare decision-making.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/in-vitro-diagnostics-market?kailas

Why In-Vitro Diagnostics Is a Highly Sellable Market

In-vitro diagnostics is highly sellable because it is a core diagnostics category with demand across multiple high-volume and high-value clinical areas. Unlike narrow testing markets that depend on one disease area, IVD serves infectious disease testing, oncology diagnostics, cardiology testing, diabetes monitoring, autoimmune disease assessment, nephrology, drug testing and genetic testing. This breadth makes the category commercially resilient because diagnostic demand is recurring, medically necessary and closely tied to treatment decisions.

The market is also attractive because IVD supports both centralized and decentralized healthcare models. Tests can be performed in diagnostic laboratories, hospitals, healthcare facilities and home environments, using systems ranging from handheld devices to complex automated laboratory instruments. This flexibility allows IVD to serve emergency care, routine screening, chronic disease management, precision oncology, infectious disease surveillance and point-of-care testing.

Chronic Disease Burden Creates Recurring Diagnostic Demand

The rising prevalence of chronic diseases is one of the strongest demand drivers for IVD. DataM Intelligence notes that IVD tests support early detection and ongoing monitoring of conditions such as diabetes, cardiovascular diseases and cancers, helping clinicians track disease progression and adjust treatment plans. This makes diagnostics a repeated-use healthcare category rather than a one-time purchase market.

The underlying disease burden is substantial. WHO reported that the number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022, creating a large long-term need for glucose monitoring, laboratory testing and treatment follow-up. Cardiovascular diseases also remain the leading cause of death globally, accounting for an estimated 19.8 million deaths in 2022, which strengthens demand for cardiac biomarkers, lipid panels, coagulation testing and related diagnostic workflows.

Oncology and Genetic Testing Strengthen the Precision Medicine Case

Oncology is one of the most important application areas for in-vitro diagnostics because cancer care increasingly depends on early detection, tumor classification, biomarker testing and therapy selection. WHO reported an estimated 20 million new cancer cases in 2022 and projected more than 35 million new cancer cases by 2050, showing the scale of future diagnostic need.

Genetic testing and companion diagnostics are also expanding the market's strategic relevance. FDA defines a companion diagnostic as a medical device, often an in-vitro device, that provides information essential for the safe and effective use of a corresponding drug or biological product. This makes IVD central to precision oncology and targeted therapy selection, particularly where treatment decisions depend on biomarker status, mutation testing or therapy-response prediction.

Infectious Disease Testing Keeps IVD Essential to Public Health Readiness

Infectious disease testing remains a major application area because health systems require rapid and reliable detection of bacterial, viral and parasitic pathogens. DataM Intelligence identifies infectious diseases as a core IVD application and highlights product innovation such as ELITechGroup's GI Bacterial PLUS ELITe MGB Kit, which targets pathogens linked to foodborne and waterborne gastrointestinal infections.

Recent product activity also shows how IVD supports outbreak response and public health surveillance. DataM Intelligence notes that BD and CerTest Biotec received U.S. FDA emergency use authorization for a PCR test for Mpox virus detection, underscoring the role of molecular diagnostics in responding to emerging infectious disease threats.

Instruments Segment Holds a Strategic Market Position

The instruments segment is expected to hold a significant position in the in-vitro diagnostics market. Instruments such as analyzers, PCR machines, immunoassay systems and next-generation sequencing platforms are essential for disease detection, analysis and monitoring. DataM Intelligence notes that advanced IVD instruments offer high precision, automation and faster processing times, which are increasingly important as laboratories handle higher testing volumes across chronic disease, infectious disease and personalized medicine applications.

Technology innovation is strengthening the segment's value. Automation, miniaturization, point-of-care formats and real-time data transfer are improving diagnostic workflow efficiency and patient management. In January 2024, HORIBA Medical launched HELO 2.0, a high-throughput automated hematology platform with CE-IVDR approval, designed for mid- to large-scale laboratories requiring scalable hematology testing capacity.

Point-of-Care Testing and Home Diagnostics Expand Market Accessibility

Point-of-care diagnostics and self-testing are making IVD more accessible by bringing testing closer to patients. This shift is especially important for diabetes monitoring, infectious disease testing and urgent-care diagnostics, where faster results can support quicker clinical decisions. DataM Intelligence includes POC diagnostics and self-blood-glucose monitoring among the key IVD technique categories, reflecting the market's movement toward decentralized testing models.

This trend strengthens the market's commercial durability. Central laboratories remain important for complex testing, but point-of-care and home-based diagnostics create new demand channels by reducing turnaround time, improving convenience and supporting chronic disease self-management. As healthcare systems prioritize earlier diagnosis and lower-cost care delivery, decentralized IVD technologies are expected to become more important.

North America Leads with Strong Testing Volume and Innovation

North America is expected to hold a significant share of the global in-vitro diagnostics market, supported by chronic disease burden, novel test launches, product advancements and regulatory confidence. DataM Intelligence notes that approximately 3.3 billion IVD tests are conducted annually in the U.S., ranging from simple reagent-based tests to advanced genetic tests that can help predict cancer therapy response.

The region also benefits from molecular diagnostics, point-of-care testing adoption, strong reimbursement structures and key company investments. DataM Intelligence cites Veracyte's multi-year agreement with Illumina to develop and offer molecular tests as decentralized IVD tests on Illumina's NextSeq 550Dx next-generation sequencing instrument, showing how advanced testing platforms are supporting broader access to precision diagnostics.

Asia Pacific Emerges as the Fastest-Growing Region

Asia Pacific is expanding at the fastest pace in the global IVD market due to rising prevalence of chronic diseases, infectious diseases and aging populations. DataM Intelligence notes that growing awareness of early disease detection, increasing adoption of personalized medicine and a shift toward point-of-care diagnostics are contributing to regional market expansion.

The region's growth outlook is supported by healthcare infrastructure investment, rising testing volumes and expanding access to advanced diagnostic solutions. As major Asia Pacific economies strengthen laboratory capacity and adopt molecular diagnostics, immunoassays and point-of-care platforms, the region is expected to become a major demand center for IVD products and services.

Cost of Advanced Diagnostics Remains a Key Barrier

Despite strong market fundamentals, the high cost of advanced diagnostics remains a restraint. DataM Intelligence notes that technologies such as molecular diagnostics, next-generation sequencing and high-throughput systems require expensive equipment, specialized technology and significant maintenance investment. These costs can limit adoption in lower-resource settings and create access challenges for smaller laboratories.

This barrier also creates a strategic opportunity. Solutions that reduce per-test cost, improve automation, simplify workflow and expand point-of-care access are likely to gain stronger adoption. The market's next phase will depend on balancing test accuracy, affordability, regulatory compliance and operational efficiency.

Competitive Landscape: Global Diagnostics Leaders Compete on Scale, Automation and Test Menu Depth

The global in-vitro diagnostics market includes major players such as bioMérieux, Becton, Dickinson and Company, Beckman Coulter, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Abbott Laboratories, Qiagen NV, FUJIFILM Holdings Corporation, Sysmex Corporation and Siemens Healthineers AG. These companies compete across instruments, reagents, molecular diagnostics, immunoassays, hematology, microbiology, tissue diagnostics, software and services.

Competition is expected to intensify around automation, molecular testing, decentralized diagnostics, high-throughput platforms, companion diagnostics, digital connectivity, laboratory workflow optimization and regional expansion. Companies that can deliver accurate, scalable and cost-effective testing across infectious disease, oncology, cardiology, diabetes and genetic testing are likely to remain strongly positioned.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=in-vitro-diagnostics-market?kailas

Strategic Outlook: IVD Becomes a Core Layer of Preventive, Personalized and Chronic Care

The in-vitro diagnostics market is positioned for steady long-term expansion because it sits at the center of modern healthcare decision-making. Infectious disease management requires rapid detection. Oncology increasingly requires biomarker and genetic testing. Cardiology depends on early risk identification and biomarker monitoring. Diabetes requires recurring measurement and treatment follow-up. Genetic testing supports personalized medicine and companion diagnostic strategies.

With the market projected to rise from US$84.90 billion in 2024 to US$131.68 billion by 2032, IVD is becoming one of the most commercially durable diagnostics categories globally. The next phase of growth will be shaped by molecular diagnostics, point-of-care testing, automation, companion diagnostics, self-testing, chronic disease monitoring and Asia Pacific adoption momentum. Because IVD supports diagnosis, treatment selection, disease monitoring and public health readiness, it remains a core, high-value and highly sellable healthcare market.

About the Report

The In-Vitro Diagnostics Market report by DataM Intelligence analyzes the market by product type, technique type, application, end-user and region. Product coverage includes instruments, reagents, software and services and others. Technique coverage includes immunoassays, POC diagnostics, molecular diagnostics, hematology, tissue diagnostics, microbiology, self-blood-glucose monitoring and others. Application coverage includes infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, drug testing and others across North America, Latin America, Europe, Asia Pacific, the Middle East and Africa.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.